Table 4. Outcome results according to XPD and XRCC1–3 polymorphisms in P vs non-P regimens.
|
XPD Lys751Gln |
XRCC1 |
XRCC3 |
|||
---|---|---|---|---|---|---|
Lys/LysNo. 37 | Gln/−No. 60 | Gln/GlnNo. 11 | Arg/−No. 82 | Met/MetNo. 19 | Thr/−No. 78 | |
RR (%) | ||||||
P | 47.6 | 35.7 | 66.7 | 34.2 | 37.5 | 41.5 |
Non-P | 31.3 | 21.9 | 0 | 29.3 | 27.3 | 24.3 |
OR (95% CI) | 1.75 (0.44–7.00) | 2.06 (0.65–6.54) | 19.41 (0.53–706.26) | 1.21 (0.48–3.09) | 1.76 (0.24–12.69) | 2.05 (0.76–5.51) |
P-valuea | 0.858 | 0.143 | 0.891 | |||
Median PFS (mos) | ||||||
P | 6.9 (2.8–12.4) | 6.8 (4.3–7.4) | 7.5 (0.8–NE) | 6.6 (3.9–7.4) | 6.8 (0.5–13.8) | 6.9 (3.9–7.7) |
Non-P | 5.0 (3.5–7.5) | 5.3 (2.6–8.1) | 2.9 (2.0–8.7) | 5.1 (3.6–7.5) | 4.9 (2.1–8.7) | 5.1 (3.4–7.5) |
HR (95% CI) | 0.83 (0.43–1.62) | 0.90 (0.54–1.51) | 0.20 (0.05–0.76) | 0.98 (0.63–1.52) | 0.59 (0.22–1.53) | 0.93 (0.59–1.46) |
P-valuea | 0.842 | 0.029 | 0.396 | |||
Median OS (mos) | ||||||
P | 9.2 (3.6–18.2) | 11.2 (7.1–15.7) | 16.6 (0.8–NE) | 9.2 (6.4–15.7) | 7.9 (1.1–32.5) | 12.3 (6.7–15.7) |
Non-P | 14.9 (5.1–23.3) | 11.3 (6.3–23.0) | 36.8 (10.3–38.7) | 12.5 (6.3–17.0) | 15.6 (2.8–28.1) | 12.5 (9.7–17.0) |
HR (95% CI) | 1.11 (0.57–2.17) | 1.13 (0.67–1.91) | 1.07 (0.28–4.05) | 1.11 (0.71–1.73) | 1.21 (0.47–3.12) | 1.10 (0.70–1.75) |
P-valuea | 0.975 | 0.960 | 0.86 |
Abbreviations: CI=confidence interval; HR=hazard ratio; mos=months; NE=not estimable; non-P=non-platinum; OR=odds ratio; OS=overall survival; P=platinum; PFS=progression-free survival; RR=response rate; XPD=xeroderma pigmentosum group D; XRCC1=X-ray cross complementing group 1; XRCC3=X-ray cross complementing group 3.
Test of interaction.